Oral Leukoplakia Clinical Trial
Official title:
M4OC-Prevent: Metformin for Oral Cancer Prevention
Verified date | December 2023 |
Source | National Cancer Institute (NCI) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase IIa trial studies how well metformin hydrochloride works in preventing oral cancer in patients with an oral premalignant lesion (oral leukoplakia or erythroplakia). Oral premalignant lesions look like red or whitish plaques or lesions in the mouth that do not rub off and can be associated with a higher risk of cancer. Metformin hydrochloride may help prevent oral cancer from forming in patients with an oral premalignant lesion.
Status | Active, not recruiting |
Enrollment | 26 |
Est. completion date | December 22, 2024 |
Est. primary completion date | October 12, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Participants with oral leukoplakia or erythroplakia with mild, moderate, or severe histologic dysplasia, or hyperplasia not associated with mechanical factors such as ill-fitted dentures - Measurable disease - minimum lesion size of 8 x 3 mm before initial biopsy - Karnofsky performance status >= 70% - Leukocytes >= 3,000/microliter - Absolute neutrophil count >= 1,000/microliter - Platelets >= 100,000/microliter - Total bilirubin =< 1.5 × institutional upper limit of normal (ULN) - Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =<1.5 × institutional ULN - eGFR > 40 mL/min using the Cockcroft-Gault equation - Life expectancy > 3 months - Willing to use adequate contraception (barrier method, abstinence, subject has had a vasectomy or partner is using effective birth control or is postmenopausal) for the duration of study participation - Ability to take oral medication - Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: - Patients with diabetes who are taking insulin or oral agents - History of diabetic ketoacidosis - Participants may not be receiving any other investigational agents within past 3 months - History of allergic reactions attributed to compounds of similar chemical composition to metformin or prior use of metformin within the last year - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, human immunodeficiency virus (HIV)-positive, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements - Oral carcinoma in situ - History of chronic alcohol use or abuse defined as any one of the following: a) average consumption of 3 or more alcohol containing beverages daily in the past 12 months; b) consumption of 7 or more alcoholic beverages within a 24 hour (hr) period in the past 12 months - Glycated hemoglobin (HbA1c) > 8% - Pregnancy or nursing women - Acute or chronic liver disease, evidence of hepatitis (infectious or autoimmune), cirrhosis or portal hypertension - History of renal disease - History of prior head and neck squamous cell carcinoma (HNSCC) unless curatively treated for >= 1 year - Have received chemotherapy and/or radiation for any malignancy (excluding non-melanoma skin cancer and cancers confined to organs with removal as only treatment) in the past 2 years; ongoing adjuvant hormonal therapy for breast cancer is allowed |
Country | Name | City | State |
---|---|---|---|
Canada | BC Cancer Research Centre | Vancouver | British Columbia |
Canada | University of British Columbia Hospital | Vancouver | British Columbia |
United States | University of Minnesota/Masonic Cancer Center | Minneapolis | Minnesota |
United States | UC San Diego Medical Center - Hillcrest | San Diego | California |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States, Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change in Saliva Microbiome Analyzed Using Flow Cytometry | This will characterize changes in the saliva microbiome before and after metformin intervention, including both the absolute microbial load and taxonomic composition. Will first evaluate changes in alpha diversity among matched pairs using non-parametric analogous Wilcoxon rank-sum test (Mann-Whitney test). To test for significant differences in beta diversity (e.g. if pretreatment and post-treatment samples cluster in principle coordinates analysis space), permutational multivariate analysis of variance (PERMANOVA) will be used. | Baseline to up to 14 weeks | |
Other | Microbiome Signatures Correlated With Treatment Response | Will first evaluate changes in alpha diversity among matched pairs using non-parametric analogous Wilcoxon rank-sum test (Mann-Whitney test). To test for significant differences in beta diversity (e.g. if pretreatment and post-treatment samples cluster in principle coordinates analysis space), PERMANOVA will be used. | Baseline to up to 14 weeks | |
Primary | Clinical Response to Metformin Intervention | Number of participants with complete and partial clinical response to metformin intervention.
Criteria for complete and partial clinical response are: Complete Response (CR): Disappearance of all evidence of lesion(s). Partial Response (PR): Greater than or equal to 50% reduction in the sum of the products of diameters of lesion(s) measurable at baseline. Non-measurable lesion(s) may not increase greater than or equal to 25% in size and no new lesion may appear. |
Baseline to up to 14 weeks | |
Secondary | Histologic Response to Metformin Intervention | Number of participants with complete and partial histologic response to metformin intervention.
Criteria for complete and partial histologic response are: Complete Response (CR): Complete reversal of dysplasia or hyperplasia to normal epithelium in the target lesion. Partial Response (PR): Improvement of the degree of dysplasia or hyperplasia in the target lesion. |
Baseline to up to 14 weeks | |
Secondary | Changes in Cell Proliferation and Its Molecular Targets | Nonparametric methods, e.g. signed rank test, will be performed to evaluate each of the changes in tissue, serum, and saliva markers. | Baseline to up to 14 weeks | |
Secondary | Changes in Frequent Dysregulated Molecular Mechanisms and OCT Expression | Nonparametric methods, e.g. signed rank test, will be performed to evaluate each of the changes in tissue, serum, and saliva markers. A univariate logistic regression model with the clinical response as the outcome variable will be fitted to explore if any of the expression of frequent dysregulated mechanisms and OCT3 level are associated with the clinical response to metformin hydrochloride. | Baseline to up to 14 weeks | |
Secondary | Impact of Genomic Alterations on the Biological and Biochemical Consequences and Clinical Response to Metformin Hydrochloride | Nonparametric methods, e.g. signed rank test, will be performed to evaluate each of the changes in tissue, serum, and saliva markers. A univariate logistic regression model with the clinical response as the outcome variable will be fitted to explore if any genomic alterations are associated with the clinical response to metformin hydrochloride. | Up to 14 weeks | |
Secondary | Change in Measurements of Metformin Hydrochloride Concentrations in Serum and Saliva | Nonparametric methods, e.g. signed rank test, will be performed to evaluate each of the changes in tissue, serum, and saliva markers. | Baseline to up to 14 weeks | |
Secondary | Change in Serum Metabolic Markers | Nonparametric methods, e.g. signed rank test, will be performed to evaluate each of the changes in tissue, serum, and saliva markers. | Baseline to up to 14 weeks | |
Secondary | Change in Serum and Saliva Inflammatory and Angiogenic Cytokines | Nonparametric methods, e.g. signed rank test, will be performed to evaluate each of the changes in tissue, serum, and saliva markers. | Baseline to up to 14 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT05505539 -
Intralesional 5-fluorouracil Injection for the Treatment of Oral Leukoplakia
|
Phase 1 | |
Terminated |
NCT00176566 -
A Phase II Trial to Assess the Effects of Green Tea in Oral Leukoplakia
|
Phase 2 | |
Completed |
NCT03682562 -
Diagnostic Accuracy of Salivary DNA Integrity Index in Oral Malignant and Premalignant Lesions
|
||
Completed |
NCT04153266 -
Oral Epithelial Dysplasia Informational Needs Questionnaire
|
||
Completed |
NCT04712929 -
Candida Associated Cytokines in Oral Leukoplakia
|
||
Completed |
NCT03031899 -
Comparison or Rose Bengal and Toluidine Blue Staining for Lesion Detection Efficacy
|
||
Terminated |
NCT00571558 -
Photodynamic Therapy Using Aminolevulinic Acid in Treating Patients With Oral Leukoplakia
|
Phase 1 | |
Recruiting |
NCT06321003 -
SYsteMatical Trained learnIng aLgorithms for Oral carcInogenesiS Interpretation by Optical Coherence Tomography
|
||
Not yet recruiting |
NCT04732741 -
Diagnostic Accuracy of Salivary Gamma-synuclein in Oral Malignant and Premalignant Lesions
|
||
Completed |
NCT00369174 -
Rosiglitazone Maleate in Treating Patients With Oral Leukoplakia
|
Phase 2 | |
Completed |
NCT00099021 -
Pioglitazone Hydrochloride in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia
|
Phase 2 | |
Not yet recruiting |
NCT05727761 -
Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia
|
Phase 2 | |
Recruiting |
NCT05942794 -
Identification of Oral Lesions Through an Autofluorescence System
|
N/A | |
Completed |
NCT00330382 -
Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia
|
Phase 2 | |
Recruiting |
NCT05237960 -
Metformin for the Prevention of Oral Cancer in Patients With Oral Leukoplakia or Erythroplakia
|
Phase 2 | |
Not yet recruiting |
NCT06256809 -
Analyzing Handprint Patterns to Predict Oral Cancer Risks: A Comparative Study
|
||
Completed |
NCT00951379 -
Pioglitazone for Oral Premalignant Lesions
|
Phase 2 | |
Recruiting |
NCT04251845 -
Evaluation of Effect of Topical Melatonin in Treatment of Oral Leukoplakia
|
N/A | |
Terminated |
NCT04079491 -
Intra and Extra Oral Inspection of Oral Mucosa
|
||
Recruiting |
NCT00767442 -
Least Invasive Nonlinear Light Microscopy
|
N/A |